tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders StocksTop Gainers/ Losers/ Active StocksMost Visited WebsitesDividend StocksAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by Upside
New
Top ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
New
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock ScreenerETF Screener
Popular
Trending StocksDaily Analyst RatingsCompare StocksCompare ETFsPenny Stock ScreenerTechnical Analysis ScreenerDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Personal Finance CenterMortgagesLoansInvesting & RetirementSpending & Savings
Calculators
401k Retirement CalculatorMortgage Calculator
Popular
Compound Interest CalculatorDollar Cost Averaging
New
Student Loan CalculatorAuto Loan Calculator
Education
How To Use TipRanksTipRanks LabsWebinar CenterGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsTop Online BrokersBecome an Affiliate
Follow Us
NewsTrendingPortfolio
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Top ETFs
Top Smart Score Stocks
Popular
Earnings
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
Top Insiders Stocks
Top Gainers/ Losers/ Active Stocks
Most Visited Websites
Dividend Stocks
AI Stocks
Largest Companies by Market Cap
ETFs
ETF Center
Top ETFs by Upside
New
Top ETFs by Smart Score
Top Gainers/ Losers/ Active ETFs
Options
Options Market Overview
Unusual Options Activity
Popular
Most Active Options
Options Volume Leaders
Commodities
Gold
New
Crypto
Crypto Center
Bitcoin
Popular
Ethereum
Currency
Currency Center
EUR/USD
Pro Newsletters
Smart Investor
Popular
Research Tools
Stock Screener
ETF Screener
Popular
Trending Stocks
Daily Analyst Ratings
Compare Stocks
Compare ETFs
Penny Stock Screener
Technical Analysis Screener
Daily Insider Trading Tracker
Calendars
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Economic Indicators
Economic Indicators Center
Inflation Rate
Unemployment Rate
Federal Funds Rate
Calculators
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Dollar Cost Averaging
New
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
News
Portfolio
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Calculators
Compound Interest Calculator
New
Mortgage Calculator
Popular
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Webinar Center
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
Follow Us

SLRN Stock Latest News

Acelyrin to present 16-week data from Phase 2b/3 trial of izokibep
The FlyAcelyrin to present 16-week data from Phase 2b/3 trial of izokibep
1M ago
SLRN
Acelyrin price target raised to $18 from $16 at H.C. Wainwright
PremiumThe Fly
Acelyrin price target raised to $18 from $16 at H.C. Wainwright
2M ago
SLRN
Acelyrin management to meet virtually with Piper Sandler
PremiumThe Fly
Acelyrin management to meet virtually with Piper Sandler
2M ago
SLRN
Acelyrin management to meet virtually with Piper Sandler
PremiumThe Fly
Acelyrin management to meet virtually with Piper Sandler
2M ago
SLRN
SLRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
PremiumPre-Earnings
SLRN Earnings Report this Week: Is It a Buy, Ahead of Earnings?
2M ago
SLRN
ACELYRIN, INC. Appoints Mina Kim as New CEO
PremiumCompany AnnouncementsACELYRIN, INC. Appoints Mina Kim as New CEO
2M ago
8K
SLRN
Acelyrin provides business and milestone update
PremiumThe Fly
Acelyrin provides business and milestone update
2M ago
SLRN
Acelyrin CEO Shao-Lee Lin steps down, Mina Kim succeeding
PremiumThe Fly
Acelyrin CEO Shao-Lee Lin steps down, Mina Kim succeeding
2M ago
SLRN
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
PremiumPress Releases
ACELYRIN, INC. Provides Business Update and Highlights Key Upcoming Milestones
2M ago
SLRN
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
PremiumPress Releases
ACELYRIN, INC. to Report First Quarter 2024 Financial Results and Corporate Update on May 13, 2024
2M ago
SLRN
Acelyrin reports FY23 EPS ($5.43), consensus ($7.40)
PremiumThe Fly
Acelyrin reports FY23 EPS ($5.43), consensus ($7.40)
3M ago
SLRN
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
PremiumPress Releases
ACELYRIN, INC. Reports Full Year 2023 Financial Results and Recent Highlights
3M ago
SLRN
Viridian Therapeutics price target lowered to $25 from $29 at B. Riley
PremiumThe FlyViridian Therapeutics price target lowered to $25 from $29 at B. Riley
4M ago
SLRN
VRDN
Acelyrin price target raised to $13 from $11 at Wells Fargo
PremiumThe Fly
Acelyrin price target raised to $13 from $11 at Wells Fargo
4M ago
SLRN
XERS
ACELYRIN Reports Promising Trials for Thyroid Eye Disease Drug
PremiumCompany Announcements
ACELYRIN Reports Promising Trials for Thyroid Eye Disease Drug
4M ago
8K
SLRN
Acelyrin announces phase 1/2 proof-of-concept data for lonigutamab
PremiumThe Fly
Acelyrin announces phase 1/2 proof-of-concept data for lonigutamab
4M ago
SLRN
Acelyrin Inc options imply 7.3% move in share price post-earnings
PremiumThe Fly
Acelyrin Inc options imply 7.3% move in share price post-earnings
4M ago
SLRN
Acelyrin says Phase 2b/3 trial of izokibep met primary endpoint
PremiumThe Fly
Acelyrin says Phase 2b/3 trial of izokibep met primary endpoint
4M ago
SLRN
ACELYRIN Reports Positive Izokibep Trial Results, Transitions Services
PremiumCompany Announcements
ACELYRIN Reports Positive Izokibep Trial Results, Transitions Services
4M ago
8K
SLRN
ACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit – Improving Quality of Life for Patients
PremiumPress ReleasesACELYRIN, INC. Announces Long-term 32-Week Data from the Phase 2b Trial of Izokibep in Hidradenitis Suppurativa Demonstrating Sustained Responses and Deepening Clinical Benefit – Improving Quality of Life for Patients
4M ago
SLRN
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
PremiumPress Releases
ACELYRIN, INC. Announces Positive Top-line Results from Its Global Phase 2b/3 Clinical Trial of Izokibep in Psoriatic Arthritis
4M ago
SLRN
Viridian Therapeutics price target lowered to $37 from $39 at Wells Fargo
PremiumThe Fly
Viridian Therapeutics price target lowered to $37 from $39 at Wells Fargo
4M ago
SLRN
VRDN

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >